Gluten derived from wheat and related Triticeae can induce gluten sensitivity as well as celiac disease. Consequently, gluten content in foods labeled "gluten-free" is regulated. Determination of potential contamination in such foods is achieved using immunoassays based on monoclonal antibodies (mAbs) that recognize specific epitopes present in gluten. However, food-processing measures can affect epitope recognition. In particular, preparation of wheat protein isolate through deamidation of glutamine residues significantly limits the ability of commercial gluten testing kits in their ability to recognize gluten. Adding to this concern, evidence suggests that deamidated gluten imparts more pathogenic potential in celiac disease than native gluten. To address the heightened need for antibody-based tools that can recognize deamidated gluten, we have generated a novel mAb, 2B9, and subsequently developed it as a rapid lateral flow immunoassay. Herein, we report the ability of the 2B9-based lateral flow device (LFD) to detect gluten from wheat, barley, and rye and deamidated gluten down to 2 ppm in food as well as its performance in food testing.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jafc.5b06085 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Suboptimal adherence to a gluten-free diet in adults with both type 1 diabetes and celiac disease using urinary gluten immunogenic peptide measurement.
Scand J Gastroenterol
December 2024
Norwegian Coeliac Disease Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Objectives: Concurrent type 1 diabetes (T1D) and celiac disease (CeD) pose challenges in insulin dosage adjustments and gluten-free dietary adherence. Urine testing for gluten immunogenic peptides (GIP) is a new method to detect gluten exposure within the last 3-12 h. Our aims were to compare gluten-free dietary adherence between T1D + CeD and CeD individuals and evaluate urinary GIP testing in an outpatient setting.
View Article and Find Full Text PDFOligomerization of 33-mer Gliadin Peptides: Supramolecular Assemblies in Celiac Disease.
ChemMedChem
December 2024
Molecular Cell Biology, Faculty of Medicine, Ruhr University Bochum, Universitätsstr. 150, 44801, Bochum, Germany.
The 33-mer gliadin peptide and its deamidated derivative, known as 33-mer DGP, are proteolytically resistant peptides central to the pathomechanism of celiac disease (CeD), the autoimmune presentation of gluten-related disorders (GRD). Both peptides can form spontaneous oligomers in the nanomolar concentration, leading to the formation of nanostructures. In other protein-related diseases, oligomers and aggregates are central in their pathomechanism; therefore, it was hypothesized that the oligomerization of proteolytical-resistant 33-mer gliadin peptides could be an underrecognized disease trigger.
View Article and Find Full Text PDFReview article: Faecal biomarkers for assessing small intestinal damage in coeliac disease and environmental enteropathy.
Aliment Pharmacol Ther
October 2024
Department of Pediatric Research, Faculty of Medicine, University of Oslo, Oslo, Norway.
Article Synopsis
- The study investigates the potential of using stool samples as non-invasive biomarkers to evaluate small intestinal damage in conditions like coeliac disease and environmental enteropathy, where traditional biopsy methods are currently used.
- A systematic search led to the inclusion of 35 relevant studies focusing on various faecal markers, such as faecal calprotectin and antibodies related to gluten sensitivity, which showed mixed results in their reliability for assessment.
- The authors conclude that more research is necessary to identify consistent and reliable faecal biomarkers that can accurately reflect small intestinal mucosal damage, particularly in environmental enteropathy.
Structural and mechanistic analysis of Ca-dependent regulation of transglutaminase 2 activity using a Ca-bound intermediate state.
Proc Natl Acad Sci U S A
July 2024
Department of Chemistry, Stanford University, Stanford, CA 94305.
Mammalian transglutaminases, a family of Ca-dependent proteins, are implicated in a variety of diseases. For example, celiac disease (CeD) is an autoimmune disorder whose pathogenesis requires transglutaminase 2 (TG2) to deamidate select glutamine residues in diet-derived gluten peptides. Deamidation involves the formation of transient γ-glutamyl thioester intermediates.
View Article and Find Full Text PDFTranscriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease.
Nat Immunol
July 2024
Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.
Article Synopsis
- Transglutaminase 2 (TG2) is crucial in the development of celiac disease by modifying gluten peptides, leading to a heightened immune response against gluten.
- The study evaluates the effectiveness of the TG2 inhibitor ZED1227 in preventing gluten-induced damage in celiac patients on a gluten-free diet, revealing that it significantly safeguards intestinal health at the molecular level.
- Findings indicate that ZED1227 treatment helps maintain healthy gene expression related to the gut's structure and function, and suggest a potential benefit in personalized treatment strategies based on specific genetic markers in celiac patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!